Evercore ISI Sticks to Its Hold Rating for Ionis Pharmaceuticals Inc (IONS)

In a report released yesterday, Joshua Schimmer from Evercore ISI maintained a Hold rating on Ionis Pharmaceuticals Inc (IONSResearch Report), with a price target of $76. The company’s shares opened today at $68.15.

According to TipRanks.com, Schimmer is a 5-star analyst with an average return of 11.4% and a 50.4% success rate. Schimmer covers the Healthcare sector, focusing on stocks such as Akero Therapeutics Inc, Audentes Therapeutics, and CymaBay Therapeutics.

The word on The Street in general, suggests a Hold analyst consensus rating for Ionis Pharmaceuticals Inc with a $69.25 average price target, representing a 1.6% upside. In a report released yesterday, Cowen & Co. also maintained a Hold rating on the stock.

See today’s analyst top recommended stocks >>

The company has a one-year high of $86.58 and a one-year low of $43.27. Currently, Ionis Pharmaceuticals Inc has an average volume of 1.35M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs.